Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man

Cohn, Keith; Sakai, Fumikazu; Langston, Manly F.

doi:10.1016/0002-8703(75)90504-9

Cited by 47 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the angiographic analyses the incidence of progression in the placebo treatment group was assumed to be 0.45 (45% of patients in the placebo treatment group demonstrating "progression"--however defined--over a 3-year period) [3,4,7,8,[34][35][36][37][38][39][40]. Thus, for a test with 80% power at a two-sided 5% significance level to detect a 30% reduction (to 0.315) in the quinapril treatment group, 203 patients are required per treatment group.…”

Section: Methodsmentioning

confidence: 99%

The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention

Texter¹,

Lees

Pitt

et al. 1993

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Summary. The rationale, trial design, and statistical aspects of QUIET, the QUinapril Ischemic Event Trial, are described. QUIET is a prospective, double-blind placebocontrolled study that will assess the ability of the angiotensin-converting enzyme (ACE) inhibitor quinapril to reduce the rate of cardiac ischemic events and to slow or prevent the development of coronary artery atherosclerosis as assessed by serial angiography in a normolipidemic population without left ventricular dysfunction. The study began in September 1991 and has completed recruitment with 1740 patients across 38 centers (28 U.S., 4 Canada, 6 Europe) by the end of 1992. Patients are randomized to 20 mg of quinapril or placebo once daily and continue in the study for 3 years. Study completion is projected for 1995.

show abstract

Section: Methodsmentioning

confidence: 99%

The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention

Texter¹,

Lees

Pitt

et al. 1993

Cardiovasc Drug Ther

View full text Add to dashboard Cite

show abstract

Determinants of Atherosclerosis Progression and Regression

Brooks¹

1978

Arch Surg

View full text Add to dashboard Cite

Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts

Blankenhorn¹

1987

JAMA

1,395

248

View full text Add to dashboard Cite

The Cholesterol-Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol hydrochloride and niacin therapy in 162 nonsmoking men aged 40 to 59 years with previous coronary bypass surgery. During two years of treatment there was a 26% reduction in total plasma cholesterol, a 43% reduction in low-density lipoprotein cholesterol, plus a simultaneous 37% elevation of high-density lipoprotein cholesterol. This resulted in a significant reduction in the average number of lesions per subject that progressed (P less than .03) and the percentage of subjects with new atheroma formation (P less than .03) in native coronary arteries. Also, the percentage of subjects with new lesions (P less than .04) or any adverse change in bypass grafts (P less than .03) was significantly reduced. Deterioration in overall coronary status was significantly less in drug-treated subjects than placebo-treated subjects (P less than .001). Atherosclerosis regression, as indicated by perceptible improvement in overall coronary status, occurred in 16.2% of colestipol-niacin treated vs 2.4% placebo treated (P = .002).

show abstract

Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man

Cited by 47 publications

References 12 publications

The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention

The QUinapril Ischemic Event Trial (QUIET) design and methods: Evaluation of chronic ACE inhibitor therapy after coronary artery intervention

Determinants of Atherosclerosis Progression and Regression

Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts

Contact Info

Product

Resources

About